Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping ADHD: new brain stimulation trial aims to sharpen kids' focus

NCT ID NCT07633275

Symptom relief Sponsor: Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a non-invasive brain stimulation technique called tACS in 50 children and teens aged 6-18 with ADHD. The goal is to see if a mild electrical current applied to the scalp can improve attention and executive function. Participants will receive both real and sham stimulation in a blinded crossover design, with brain activity measured via EEG.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

38 people

The number who actually took part.

Started

Mar 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 6-18 years, Han Chinese, and right-handed; 2. Normal or corrected-to-normal vision and normal hearing; 3. Meets the DSM-5 diagnostic criteria for attention-deficit/hyperactivity disorder, predominantly inattentive presentation; 4. Meets the diagnostic threshold for inattention based on the parent-rated SNAP-IV scale; 5. Performance on the symbol cancellation test, converted to a grade-standardized score, is below the average level; 6. Has normal intelligence as confirmed by a brief intelligence assessment, with no significant emotional disorder or severe physical illness; 7. Able to cooperate with electroencephalography recording and transcranial alternating current stimulation. Exclusion Criteria: 1. Meets diagnostic criteria for other major psychiatric disorders, such as schizophrenia or bipolar disorder; 2. Has severe physical diseases, such as significant intracranial lesions, thyroid disease, epilepsy, congenital heart disease, severe hematological disease, systemic lupus erythematosus, or significant visual or hearing impairment; 3. Has known obvious brain structural abnormalities based on available cranial imaging or medical history; 4. Has severe neurological disease, a clear family history of hereditary neurological disorders, or other conditions associated with high neurological risk; 5. Has metal implants or a cardiac pacemaker in the body, or has skull defects, holes, or fractures; 6. Is currently receiving other pharmacological or behavioral treatment for ADHD, such as methylphenidate medication or behavioral intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention deficit hyperactivity disorder

Contacts and locations

Locations

  • Department of Psychiatry, The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.